Advertisement

Organisation › Details
Sanofi (Group) [since May 2011]
Sanofi-aventis is the world's third largest pharmaceutical company, ranking number one in Europe. Backed by a world-class R&D organization, Sanofi-aventis is developing leading positions in seven major therapeutic areas: cardiovascular, thrombosis, oncology, metabolic diseases, central nervous system, internal medicine, and vaccines. Sanofi-aventis is listed in Paris (EURONEXT: SAN) and in New York (NYSE: SNY). *
![]() |
Start | 2011-05-06 renamed |
Predecessor | Sanofi-Aventis (Group) | |
![]() |
Industry | pharmaceutical |
![]() |
Person | Hudson, Paul (Sanofi 201909– CEO before Novartis Head Pharma before AstraZeneca + Schering-Plough) |
Person 2 | Contamine, Jérôme (Sanofi 2009–201809 CFO RETIRED 9/18) | |
![]() |
Region | Paris |
Country | France | |
Street | 174 avenue de France | |
City | 75635 Paris | |
Tel | +33-1-5377-4000 | |
Address record changed: 2020-12-02 | ||
Basic data | Employees | I: 50,001 to 100,0 (2021-12-31) |
Currency | EUR | |
Annual sales | 37,761,000,000 (sales, net, consolidated (2021) 2021-12-31) | |
Profit | 6,279,000,000 (2021-12-31) | |
Cash | 10,098,000,000 (2021-12-31) | |
* Document for »About Section«: | ||
Record changed: 2023-07-10 |
Advertisement

More documents for Sanofi (Group) [since May 2011]
- [1] MeiraGTx Holdings plc. (10/30/23). "Press Release: MeiraGTx Announces $30 Million Strategic Investment from Sanofi; Company Pursuing Multiple Additional Strategic Opportunities". London & New York, NY....
- [2] Sanofi S.A.. (10/3/23). "Press Release: Sanofi Announces Agreement for Potential First-in-Class Vaccine against Extraintestinal Pathogenic E. coli". Paris....
- [3] Sanofi S.A.. (3/13/23). "Press Release: Sanofi to Acquire Provention Bio, Adding to Portfolio TZIELD, the First Disease-modifying Treatment for the Delay of Stage 3 Type 1 Diabetes (T1D)". Paris & Red Bank, NJ....
- [4] Avilar Therapeutics, Inc.. (2/16/23). "Press Release: Avilar Therapeutics Increases Financing to $75 Million to Advance Pipeline of Novel Extracellular Protein Degraders". Waltham, MA....
- [5] Sanofi S.A.. (1/11/23). "Press Release: Sanofi Ventures Announces Multi-year Capital Commitment from Sanofi, Increasing Evergreen Fund to $750M". Paris....
- [6] CureVac N.V.. (1/10/23). "Press Release: CureVac Appoints Alexander Zehnder as CEO from April 1, 2023". Mainz & London....
- [7] Insilico Medicine. (11/8/22). "Press Release: Insilico Medicine Signs Strategic Research Collaboration with Sanofi Worth up to $1.2 Billion". New York, NY....
- [8] Matchpoint Therapeutics, Inc.. (10/14/22). "Press Release: Matchpoint Therapeutics Launches with $100 Million to Deliver on the Promise of Precision Covalent Medicines for Immune Diseases". Cambridge, MA....
- [9] Owkin. (10/4/22). "Press Release: Owkin Appoints Sanofi’s Global Head of Partnering Alban de La Sablière as Chief Business Officer"....
- [10] Sanofi S.A.. (8/4/22). "Press Release: Sanofi and Innovent Biologics Enter Strategic Collaboration to Accelerate Development of Oncology Medicines and Expand Presence in China". Paris....
To subscribe to our free, monthly newsletter for the European life sciences, please send an e-mail to info@iito.de and simply fill the subject line with the word »LSE Newsletter«
Find more infos about advertising at [iito] web portals in our media flyer [iito] in a Nutshell [PDF file]
Advertisement

» top